Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients
Status:
Not yet recruiting
Trial end date:
2030-03-01
Target enrollment:
Participant gender:
Summary
This research is being done to learn whether drug called itacitinib, which is a novel
inflammation- and immune-lowering drug (immunosuppressant), can be given before and after
non-myeloablative peripheral blood stem cell transplantation (PBSCT; also known as a 'mini'
transplant) to help prevent certain complications such as cytokine release syndrome (CRS) for
patients with blood cancers, using peripheral blood from a relative. The investigators will
also examine if by using itacitinib the investigators can reduce the duration of MMF (other
immune suppressive drug administration posttransplant).
Phase:
Phase 1
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins